Medicis Announces FDA Approval of Its NDA for Vanos

The FDA has approved Medicis' new drug application for Vanos, a Class I corticosteroid for the treatment of plaque-type psoriasis.

Vanos is a patented corticosteroid formulation that embodies the heritage of Lidex. The unique formulation of Vanos provides doctors and patients with the convenience of a new, high-potency vehicle in the form of a cream for once or twice daily application.

The Class I corticosteroid market in the U.S. is approximately $329 million. Medicis anticipates launching Vanos to dermatologists in the quarter beginning April 2005.